Zobrazeno 1 - 10
of 46
pro vyhledávání: '"T. Cars"'
Publikováno v:
European Journal of Preventive Cardiology. 30
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): This study was sponsored by AstraZeneca. Introduction Heart failure, a common disease with a mortality on par with many cancers, is one of the costliest diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e31a59c95225619fc821c2d643ff8d5c
https://doi.org/10.1093/eurjpc/zwad125.222
https://doi.org/10.1093/eurjpc/zwad125.222
Autor:
M K Svensson, S James, A Ravn-Fischer, E Pantev, G Villa, L Schalin, T Cars, S Gustafsson, E Hagstrom
Publikováno v:
European Heart Journal. 43
Background/Introduction Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce low density lipoprotein cholesterol (LDL-C) levels by around 50% to 60%, and the risk of cardiovascular events in patients with atherosclerotic cardiovasc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d78002f65097de877d0bb7ecc76df966
https://doi.org/10.1093/eurheartj/ehac544.2680
https://doi.org/10.1093/eurheartj/ehac544.2680
Publikováno v:
European Heart Journal. 43
Background Hospital-based cardiac rehabilitation and risk factor control decreases the risk of recurrent events after acute coronary syndrome (ACS). Little is known on long-term assessment and target achievement after referral to primary care. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c9f73edc533689ac660d09f612bcc4
https://doi.org/10.1093/eurheartj/ehac544.1410
https://doi.org/10.1093/eurheartj/ehac544.1410
Autor:
M K Svensson, S James, A Ravn-Fischer, E Pantev, F Sorio-Vilela, G Villa, T Cars, S Gustafsson, E Hagstrom
Publikováno v:
European Heart Journal. 42
Background/Introduction Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) levels and the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52c93267128a4054e1c5d817f54dbf43
https://doi.org/10.1093/eurheartj/ehab724.2590
https://doi.org/10.1093/eurheartj/ehab724.2590
Publikováno v:
European Neuropsychopharmacology. 53:S636-S637
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::330b6684ba272b596cc114aa484bd6ff
https://doi.org/10.1016/j.euroneuro.2021.10.727
https://doi.org/10.1016/j.euroneuro.2021.10.727
Autor:
J. Lundberg, T. Cars, S.Å. Lööv, J. Söderling, J. Sundström, A. Leval, A. Gannedahl, C. Björkholm, M. Själin, C. Hellner
Publikováno v:
Neuroscience Applied. 1:100179
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfc5638d1c324c835243b9fa23629aa2
https://doi.org/10.1016/j.nsa.2022.100179
https://doi.org/10.1016/j.nsa.2022.100179
Autor:
B. Rive, J. Lundberg, M. Själin, C. Björkholm, A. Leval, S. Van Sanden, C. Hellner, A. Gannedahl, T. Cars
Publikováno v:
European Neuropsychopharmacology. 40:S149-S150
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bbe72d4d614b0e45e104d12b2f21442
https://doi.org/10.1016/j.euroneuro.2020.09.197
https://doi.org/10.1016/j.euroneuro.2020.09.197
Autor:
J. Lundberg, C. Hellner, A. Leval, M. Själin, M. Ek, A. Gannedahl, J. Tiihonen, S.Å. Lööv, T. Cars
Publikováno v:
European Neuropsychopharmacology. 29:S171-S172
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89e0eac636d00ea73e2c7341e56fb0d1
https://doi.org/10.1016/j.euroneuro.2019.09.266
https://doi.org/10.1016/j.euroneuro.2019.09.266
Autor:
A. Leval, B. Rive, C. Björkholm, N. Merclin, D. Umuhire, A. Gannedahl, R. Milz, C. Hellner, J. Lundberg, T. Cars
Publikováno v:
European Neuropsychopharmacology. 29:S367
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bdbbce3436d19cc0b72830d6ff74db5
https://doi.org/10.1016/j.euroneuro.2019.09.526
https://doi.org/10.1016/j.euroneuro.2019.09.526
Publikováno v:
Clinical pharmacology and therapeutics. 103(3)
Although there is no doubt about the scientific value of randomized controlled clinical trials, they are usually conducted in selected populations different from those treated in clinical practice. Therefore, it is important to optimize real-time pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::65ef573d4dbf0ccaded0fee0017b2fa1
https://pubmed.ncbi.nlm.nih.gov/28560722
https://pubmed.ncbi.nlm.nih.gov/28560722